MIA's Autumn Newsletter

12 April 2015
The latest news and information from MIA can be read in our Autumn newsletter which can be downloaded here.

Anti-PD1 immunotherapy pembrolizumab (KEYTRUDA® ) has been registered by the TGA
Australia is the first country in the world to register anti-PD1 for the first line treatment of unresectable or metastatic melanoma in adults.

MIA's Autumn Newsletter
Our Autumn newsletter has been published and we have our digital version online now.

Professor John Thompson appointed to Australian Academy of Health and Medical Sciences
Professor John Thompson, Executive Director at Melanoma Institute Australia, was one of 116 fellows appointed to the new Australian Academy of Health and Medical Sciences at a ceremony in Canberra on the 25th March.

Melanoma Institute part of $14m melanoma project grant
Federal Minister for Health, the Hon. Sussan Ley, announced more than $14 million in funding for a research program to study the molecular determinants of risk, progression and treatment response in melanoma.

Melanoma March Bibs
If you would like to download a bib for your Melanoma March, we have a selection for you to choose from, print and bring along with you on the day.

Q&A with Melanoma March Fundraisers
We did a short Q&A with two sisters who are raising funds for Melanoma March after sadly losing their mother in 2009. This is their second march and they have shared with us their fundraising tips.

Research Director Graham Mann explains where Melanoma March funds are going
We want to share with you what your valuable Melanoma March donation and fundraising goes towards and our Research Director, Graham Mann explains the national research project the funds will be going towards.

First patient recruited to the EAGLE FM Trial
Evaluation of Groin Lymphadenectomy Extent for Metastatic Melanoma (EAGLE FM) clinical trial has recruited its first patient.

Online Comments to the Pharmaceutical Benefits Advisory Committee
You are invited to provide comments for consideration by the Pharmaceutical Benefits Advisory Committee (PBAC). The PBAC will consider the registration of the anti-PD1 drug, Keytruda (pembrolizumab) at the next meeting in March.

A man of commitment
Melanoma patient Joel Allsop was congratulated today on completing his participation in the international surgical clinical trial, known as MSLT-II. He was the first person in the world to complete the 10 years of follow-up for this trial.

Melanoma March has officially launched
Melanoma Institute Australia (MIA) has officially launched the 2015 ‘Melanoma March’ initiative in Melbourne.

Melanoma March is around the corner
Help us march towards a cure for melanoma research. See where your local march is and how you can get involved.

Q&A with a PhD student
Under the leadership of world-leading melanoma pathologist Prof Richard Scolyer and medical oncologist A/Prof Georgina Long, third year PhD student, Hojabr Kakavand, is at the forefront of melanoma research.

ClinTrial Refer Melanoma App
Melanoma Institute Australia has launched a new smartphone app called ClinTrial Refer Melanoma to help busy clinicians find clinical trials for their melanoma patients.

Interview on the latest melanoma treatments
MIA's Associate Professor Georgina Long and stage 4 melanoma patient, Maria, were recently interviewed by ABC Weekend Breakfast about the latest in clincial trials and melanoma treatments.

Sunbed campaigner acknowledged as one of most influential Australians
Sunbed campaigner, Jay Allen, has been acknowledged on the honour roll of Australia’s most influential people in the non-profit sector.

A world-class organisation needs a world-class website
Today we launch the website we’ve dreamed about!

Watch Your Mate's Back kicks off soon
Our new summer campaign has you and your mates' backs covered!